Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Athersys Inc (ATHX)

Athersys Inc (ATHX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 353,353
  • Shares Outstanding, K 197,404
  • Annual Sales, $ 5,630 K
  • Annual Income, $ -44,580 K
  • 60-Month Beta -1.73
  • Price/Sales 57.12
  • Price/Cash Flow N/A
  • Price/Book 4.99
Trade ATHX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.10
  • Prior Year -0.08
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5600 +9.94%
on 10/28/20
2.0299 -15.51%
on 10/14/20
-0.2350 (-12.05%)
since 09/30/20
3-Month
1.5600 +9.94%
on 10/28/20
2.7400 -37.41%
on 08/04/20
-0.8750 (-33.78%)
since 07/30/20
52-Week
1.1300 +51.77%
on 03/13/20
4.3800 -60.84%
on 04/01/20
+0.4150 (+31.92%)
since 10/30/19

Most Recent Stories

More News
Athersys to Host Third Quarter Financial Results Call

Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2020 financial results at approximately 4:00 PM Eastern Time on Monday, November 9, 2020, and will host a conference call shortly thereafter...

ATHX : 1.7250 (-3.63%)
Do Options Traders Know Something About Athersys (ATHX) Stock We Don't?

Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.

ATHX : 1.7250 (-3.63%)
Athersys Gets FDA's RMAT Designation for Cell Therapy in ARDS

The FDA bestows a Regenerative Medicine Advanced Therapy status on Athersys' (ATHX) MultiStem cell therapy candidate for treating acute respiratory distress syndrome.

QGEN : 47.23 (-0.78%)
EBS : 89.30 (-1.62%)
ATHX : 1.7250 (-3.63%)
HZNP : 74.22 (-4.50%)
[2020-2026] Acute Respiratory Distress Syndrome Treatment Market Size, Share, Growth, Revenue, Potential, Analysis Report

Advancements in stem cell research is a major driving factor for the global acute respiratory distress syndrome treatment market growth. According to the National Centre for Biotechnology Information (NCBI),...

ATHX : 1.7250 (-3.63%)
GSK : 33.40 (-1.65%)
FDA Grants RMAT Designation to MultiStem Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome

Athersys, Inc., a leading regenerative medicine company in late-stage clinical development, announced today that MultiStem(R) cell therapy was granted Regenerative Medicine Advanced Therapy (RMAT) designation...

ATHX : 1.7250 (-3.63%)
New Strong Sell Stocks for August 25th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

FCFS : 51.74 (-0.63%)
ATHX : 1.7250 (-3.63%)
ABEV : 2.14 (-5.31%)
CENX : 6.61 (-5.71%)
ETTX : 1.6300 (-2.40%)
Athersys Reports Second Quarter 2020 Results

Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended June 30, 2020.

ATHX : 1.7250 (-3.63%)
Thinking about buying stock in SINTX Technologies, China Automotive Systems, Athersys Inc, Theratechnologies, or Biocept Inc?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SINT, CAAS, ATHX, THTX, and BIOC.

ATHX : 1.7250 (-3.63%)
BIOC : 4.28 (-2.73%)
TH.TO : 2.53 (+0.40%)
Athersys Announces Upcoming Presentations at the International Society of Cell and Gene Therapy Virtual Conference

Athersys, Inc. (NASDAQ: ATHX) announced today its participation in several sessions at this year's International Society for Cell and Gene Therapy (ISCT) virtual conference taking place May 28 - 29, 2020....

ATHX : 1.7250 (-3.63%)
Athersys Reports First Quarter 2020 Results

Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2020.

ATHX : 1.7250 (-3.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and...

See More

Key Turning Points

2nd Resistance Point 1.9633
1st Resistance Point 1.8767
Last Price 1.7250
1st Support Level 1.6667
2nd Support Level 1.5433

See More

52-Week High 4.3800
Fibonacci 61.8% 3.1385
Fibonacci 50% 2.7550
Fibonacci 38.2% 2.3715
Last Price 1.7250
52-Week Low 1.1300

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar